Preventing lung cancer in people with high-risk lung spots
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests an immunotherapy approach to stop high-risk lung spots from turning into cancer. It is for people who are current or former heavy smokers with multiple slow-growing lung nodules that are not yet ready for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a current or former smoker with a history of more than 20 pack-years (e.g., one pack a day for 20 years).
- You have at least two partly solid lung spots, with the solid part smaller than 9mm, and at least one of them has grown on a CT scan from the past year.
- Your lung nodules are not yet candidates for surgery.
- You can commit to giving blood samples (about 100 mL, or 12 tubes) at five different visits.
- You are 18 or older and in fairly good health (able to do daily activities without major help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving radiation and immunotherapy together to people with advanced lung cancer that hasn't been treated yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This study looks at lung “biomarkers” (test results from your nodule/tissue) to better predict risk of cancer coming back and to guide long-term follow-up. It may help doctors choose the best surveillance plan after surgery or other treatment for early, potentially curable lung cancer.
This trial tests whether adding a NAD+ booster (NMN) to radiation and immunotherapy can help people with advanced lung cancer. It may improve the effectiveness of the treatment and help you live longer.
This trial is testing a new treatment using your own immune cells (called NK cells) to fight leftover high-risk lung nodules that cannot be surgically removed. It is for people who have already had some cancerous nodules removed and are looking for another option.
This study looks at people with lung nodules or masses, or those at high risk for lung cancer, to improve how doctors predict cancer risk and recurrence. It combines imaging, blood tests, and tissue samples to better personalize care.
This trial tests canakinumab to lower the risk of lung cancer growing from persistent lung nodules seen on CT scans. It may help people at higher risk who have either never had lung cancer or had early lung cancer treated in the past.
Hear when a new High-risk Lung Nodules trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.